MA40937A - Acide benzoïque, dérivés d'acide benzoïque et conjugués d'acide hétéroarylcarboxylique d'oxymorphone, promédicaments, leurs procédés de fabrication et d'utilisation - Google Patents
Acide benzoïque, dérivés d'acide benzoïque et conjugués d'acide hétéroarylcarboxylique d'oxymorphone, promédicaments, leurs procédés de fabrication et d'utilisationInfo
- Publication number
- MA40937A MA40937A MA040937A MA40937A MA40937A MA 40937 A MA40937 A MA 40937A MA 040937 A MA040937 A MA 040937A MA 40937 A MA40937 A MA 40937A MA 40937 A MA40937 A MA 40937A
- Authority
- MA
- Morocco
- Prior art keywords
- oxymorphone
- benzoic acid
- conjugates
- manufacturing
- heteroarylcarboxylic
- Prior art date
Links
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 title abstract 4
- 229960005118 oxymorphone Drugs 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 239000002253 acid Substances 0.000 title abstract 2
- 150000001558 benzoic acid derivatives Chemical class 0.000 title abstract 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 title 2
- 239000005711 Benzoic acid Substances 0.000 title 1
- 235000010233 benzoic acid Nutrition 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 abstract 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 abstract 1
- 150000001242 acetic acid derivatives Chemical class 0.000 abstract 1
- 150000007513 acids Chemical class 0.000 abstract 1
- 229940111136 antiinflammatory and antirheumatic drug fenamates Drugs 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003873 salicylate salts Chemical class 0.000 abstract 1
- 230000002194 synthesizing effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/22—Bridged ring systems
- C07D221/28—Morphinans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
- C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
- C07D489/08—Oxygen atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
La présente technologie offre des compositions comprenant des acides arylcarboxyliques et, par exemple, des anti-inflammatoires non stéroïdiens (ains), des conjugués chimiquement à l'oxymorphone (4,5-α-époxy-3,14-hydroxy-17-méthylmorphinan-6-one) pour obtenir de nouveaux promédicaments/compositions d'oxymorphone, y compris des benzoates, salicylates, propionates, fénamates et acétates, qui ont un potentiel réduit en termes d'abus d'oxymorphone. La présente technologie concerne également des procédés de traitement de patients, des kits pharmaceutiques et des procédés de synthèse de conjugués selon la présente invention.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462086326P | 2014-12-02 | 2014-12-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA40937A true MA40937A (fr) | 2017-10-11 |
Family
ID=55022688
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA040937A MA40937A (fr) | 2014-12-02 | 2015-12-02 | Acide benzoïque, dérivés d'acide benzoïque et conjugués d'acide hétéroarylcarboxylique d'oxymorphone, promédicaments, leurs procédés de fabrication et d'utilisation |
Country Status (19)
Country | Link |
---|---|
US (4) | US9682076B2 (fr) |
EP (1) | EP3226907A1 (fr) |
JP (2) | JP6462877B2 (fr) |
KR (1) | KR20170094251A (fr) |
CN (1) | CN106999487A (fr) |
AU (1) | AU2015358606B9 (fr) |
BR (1) | BR112017011764A2 (fr) |
CA (1) | CA2969221C (fr) |
CL (1) | CL2017001417A1 (fr) |
CO (1) | CO2017005203A2 (fr) |
HK (1) | HK1244209A1 (fr) |
IL (1) | IL252472A0 (fr) |
MA (1) | MA40937A (fr) |
MX (1) | MX2017006935A (fr) |
NZ (1) | NZ731586A (fr) |
PH (1) | PH12017500859A1 (fr) |
RU (1) | RU2683274C2 (fr) |
SG (1) | SG11201704309YA (fr) |
WO (1) | WO2016089951A1 (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112017011764A2 (pt) | 2014-12-02 | 2018-07-10 | Kempharm, Inc. | ácido benzóico, derivados de ácido benzóico e conjugados de ácido heteroaril carboxílico de oximorfona, pro-fármacos, métodos e preparação e uso dos mesmos |
RU2657803C1 (ru) * | 2017-03-21 | 2018-06-15 | федеральное государственное бюджетное образовательное учреждение высшего образования "Алтайский государственный университет" | Средство, обладающее противовоспалительным и анальгезирующим действием |
CN111107849B (zh) * | 2017-07-20 | 2024-03-29 | 苏州润鑫达泰生物医药有限公司 | 抗滥用长效释放阿片样前药 |
EP3755704A1 (fr) * | 2018-02-23 | 2020-12-30 | Rhodes Technologies Inc. | Nouveaux composés opioïdes et leurs utilisations |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4668685A (en) | 1984-07-05 | 1987-05-26 | E.I. Du Pont De Nemours And Company | Substituted benzoate ester prodrug derivatives of 3-hydroxymorphinans, which are analgesics or narcotic antagonists |
US5965161A (en) | 1994-11-04 | 1999-10-12 | Euro-Celtique, S.A. | Extruded multi-particulates |
EP0804459A4 (fr) | 1995-01-16 | 1999-05-26 | Commw Scient Ind Res Org | Conjugues compose therapeutique - acide gras |
DE19602962A1 (de) | 1995-12-20 | 1997-07-31 | Nycomed Arzneimittel Gmbh | Neue Morphinderivate, Verfahren zu deren Herstellung und deren Verwendung |
ES2374717T3 (es) | 1999-10-29 | 2012-02-21 | Euro-Celtique S.A. | Formulaciones de hidrocodona de liberación controlada. |
WO2005032474A2 (fr) | 2003-09-30 | 2005-04-14 | New River Pharmaceuticals Inc. | Compositions pharmaceutiques pour prevenir une dose excessive ou un abus |
AU2002305816B2 (en) * | 2001-06-05 | 2008-04-10 | Psivida Us Inc. | Sustained-release analgesic compounds |
US6740641B2 (en) | 2001-07-27 | 2004-05-25 | Euro-Celtique, S.A. | Sugar derivatives of hydromorphone, dihydromorphine and dihydromorphine, compositions thereof and uses for treating or preventing pain |
US20040033253A1 (en) * | 2002-02-19 | 2004-02-19 | Ihor Shevchuk | Acyl opioid antagonists |
US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
WO2004082620A2 (fr) | 2003-03-13 | 2004-09-30 | Controlled Chemicals, Inc. | Composes et methodes pour reduire l'abus potentiel d'un medicament et pour en prolonger la duree d'action |
EP2007389A2 (fr) | 2006-04-14 | 2008-12-31 | Shire LLC | Compositions et procedes permettant d'augmenter la puissance analgesique de composes lies par liaison covalente, d'attenuer leurs effets secondaires defavorables et d'empecher leur utilisation abusive |
WO2007140272A2 (fr) * | 2006-05-26 | 2007-12-06 | Pharmacofore, Inc. | Libération régulée d'opioïdes phénoliques |
CA2668074A1 (fr) | 2006-10-31 | 2008-05-08 | David Schwaab | Systeme de masquage automatique de structures de repertoire de donnees et de fichiers enregistrees sur une memoire d'ordinateur |
WO2008101202A1 (fr) | 2007-02-16 | 2008-08-21 | Pharmacofore, Inc. | Promédicaments d'opioïdes |
US20090192095A1 (en) | 2008-01-18 | 2009-07-30 | Shire Llc | Amino acid and peptide prodrugs of opioid analgesics with reduced gi side-effects |
MX2011010448A (es) | 2009-04-02 | 2011-10-28 | Shire Llc | Profarmacos de opioides novedosos de amino acidos y peptidos enlazados a acido dicarboxilico y usos de los mismos. |
UA102916C2 (uk) | 2009-07-02 | 2013-08-27 | Кемфарм, Інк. | Композиція на основі кон'югату гідрокодону з бензойною кислотою, похідними бензойної кислоти або гетероарилкарбоновою кислотою, проліки, спосіб лікування від зловживань |
WO2011002995A1 (fr) | 2009-07-02 | 2011-01-06 | Kempharm, Inc. | Conjugués d'acide phényléthanoïque, d'acide phénylpropanoïque et d'acide phénylpropénoïque et promédicaments d'hydrocodone, leurs procédés de fabrication et d'utilisation |
US20120115778A1 (en) | 2009-07-15 | 2012-05-10 | The Trustees Of Columbia University In The City Of New York | Methods of Suppressing Appetite by the Administration of Antagonists of the Serotonin HTR1a or HTR2b Receptors or Inhibitors of TPH2 |
WO2011008636A1 (fr) | 2009-07-15 | 2011-01-20 | Mallinckrodt Inc. | Dérivés de 3-oxy-hydromorphone |
DK2453895T3 (en) * | 2009-07-16 | 2018-08-27 | Mallinckrodt Llc | (+) - MORPHINANES AS ANTAGONISTS OF TOLL-LIKE RECEPTOR 9 AND THERAPEUTIC APPLICATIONS THEREOF |
MX348262B (es) | 2009-09-08 | 2017-06-05 | Signature Therapeutics Inc * | Composiciones que comprenden profarmacos opioides con una cetona modificada que se pueden escindir enzimaticamente e inhibidores opcionales de estos. |
WO2012008984A1 (fr) * | 2010-07-16 | 2012-01-19 | Mallinckrodt Llc | (+)-morphinanes en tant qu'antagonistes des récepteurs de type toll-9 et leurs utilisations thérapeutiques |
US8685916B2 (en) | 2011-03-09 | 2014-04-01 | Signature Therapeutics, Inc. | Opioid prodrugs with heterocyclic linkers |
BR112014010099A8 (pt) | 2011-10-26 | 2018-01-16 | Kempharm Inc | ácido benzóico, derivados de ácidos benzóicos e ácidos carboxílicos heteroarílicos conjugados de hidromorfona, pró-fármacos, métodos de fabricação e uso dos mesmos. |
BR112017011764A2 (pt) | 2014-12-02 | 2018-07-10 | Kempharm, Inc. | ácido benzóico, derivados de ácido benzóico e conjugados de ácido heteroaril carboxílico de oximorfona, pro-fármacos, métodos e preparação e uso dos mesmos |
-
2015
- 2015-12-02 BR BR112017011764-9A patent/BR112017011764A2/pt not_active Application Discontinuation
- 2015-12-02 WO PCT/US2015/063351 patent/WO2016089951A1/fr active Application Filing
- 2015-12-02 RU RU2017123161A patent/RU2683274C2/ru not_active IP Right Cessation
- 2015-12-02 CA CA2969221A patent/CA2969221C/fr active Active
- 2015-12-02 SG SG11201704309YA patent/SG11201704309YA/en unknown
- 2015-12-02 MA MA040937A patent/MA40937A/fr unknown
- 2015-12-02 CN CN201580064812.5A patent/CN106999487A/zh active Pending
- 2015-12-02 NZ NZ731586A patent/NZ731586A/en not_active IP Right Cessation
- 2015-12-02 KR KR1020177017415A patent/KR20170094251A/ko active IP Right Grant
- 2015-12-02 EP EP15816302.2A patent/EP3226907A1/fr not_active Withdrawn
- 2015-12-02 MX MX2017006935A patent/MX2017006935A/es unknown
- 2015-12-02 US US14/956,642 patent/US9682076B2/en active Active
- 2015-12-02 AU AU2015358606A patent/AU2015358606B9/en not_active Ceased
- 2015-12-02 JP JP2017529821A patent/JP6462877B2/ja not_active Expired - Fee Related
-
2017
- 2017-05-08 US US15/589,158 patent/US10071091B2/en active Active
- 2017-05-09 PH PH12017500859A patent/PH12017500859A1/en unknown
- 2017-05-23 IL IL252472A patent/IL252472A0/en unknown
- 2017-05-25 CO CONC2017/0005203A patent/CO2017005203A2/es unknown
- 2017-06-02 CL CL2017001417A patent/CL2017001417A1/es unknown
-
2018
- 2018-03-16 HK HK18103710.3A patent/HK1244209A1/zh unknown
- 2018-08-03 US US16/054,578 patent/US10463660B2/en active Active
- 2018-12-27 JP JP2018244453A patent/JP2019077695A/ja not_active Withdrawn
-
2019
- 2019-09-17 US US16/573,313 patent/US10758528B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CL2017001417A1 (es) | 2018-02-09 |
HK1244209A1 (zh) | 2018-08-03 |
US10463660B2 (en) | 2019-11-05 |
RU2017123161A3 (fr) | 2019-01-09 |
EP3226907A1 (fr) | 2017-10-11 |
JP2017538696A (ja) | 2017-12-28 |
MX2017006935A (es) | 2017-08-10 |
AU2015358606B2 (en) | 2019-04-18 |
US20160151352A1 (en) | 2016-06-02 |
US20170312270A1 (en) | 2017-11-02 |
PH12017500859A1 (en) | 2017-11-06 |
US9682076B2 (en) | 2017-06-20 |
US10758528B2 (en) | 2020-09-01 |
CA2969221C (fr) | 2021-01-12 |
CA2969221A1 (fr) | 2016-06-09 |
AU2015358606B9 (en) | 2019-05-02 |
KR20170094251A (ko) | 2017-08-17 |
BR112017011764A2 (pt) | 2018-07-10 |
CO2017005203A2 (es) | 2017-08-31 |
SG11201704309YA (en) | 2017-06-29 |
US10071091B2 (en) | 2018-09-11 |
RU2683274C2 (ru) | 2019-03-27 |
RU2017123161A (ru) | 2019-01-09 |
AU2015358606A1 (en) | 2017-05-25 |
CN106999487A (zh) | 2017-08-01 |
JP2019077695A (ja) | 2019-05-23 |
WO2016089951A1 (fr) | 2016-06-09 |
JP6462877B2 (ja) | 2019-01-30 |
NZ731586A (en) | 2018-06-29 |
US20200030316A1 (en) | 2020-01-30 |
IL252472A0 (en) | 2017-07-31 |
US20180338968A1 (en) | 2018-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA39725B1 (fr) | Compositions pharmaceutiques de composés thérapeutiquement actifs | |
MA39040A1 (fr) | Nouveau traitement combiné pour la leucémie aiguë myéloïde (lam) | |
MA40111A1 (fr) | Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1 | |
MA38576A1 (fr) | Formulations de colchicine à libération prolongée et procédés d'utilisation de ces dernières | |
BR112018010650A8 (pt) | pró-fármacos de um inibidor de jak composto para o tratamento da doença inflamatória gastrointestinal | |
ECSP099239A (es) | Determinadas amidas sustituidas, método de elaboración y método de uso de las mismas | |
MA39783B1 (fr) | Dérivés de quinoxaline utiles en tant que modulateurs de la fgfr kinase | |
ECSP099238A (es) | Amidas sustituidas, método de elaboración y método de uso de las mismas | |
MA40937A (fr) | Acide benzoïque, dérivés d'acide benzoïque et conjugués d'acide hétéroarylcarboxylique d'oxymorphone, promédicaments, leurs procédés de fabrication et d'utilisation | |
MA38399A1 (fr) | Formulation sous forme de comprimé, utile pour traiter l'insuffisance cardiaque aiguë et l'insuffisance cardiaque chronique | |
MA40768B1 (fr) | Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue | |
FR3058059B1 (fr) | Composition pharmaceutique comprenant le beta-elemene, le lupeol et le 2-hydroxycinnamaldehyde et/ou le 2'-benzoyloxycinnalmaldehyde et/ou le beta-sitosterol et/ou la curcumine. | |
CO6331425A2 (es) | Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida | |
CY1122626T1 (el) | Κορτικοστεροειδες που περιεχει τις συνθεσεις των δισκιων που διασπωνται απο το στομα για την ηωσινοφιλικη οισοφαγιτιδα | |
MA37742A1 (fr) | Dérivés d'oestra-1,3,5 (10), 16-tétraène substitués en position 3, leurs procédés de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour la fabrication de médicaments | |
ECSP16084317A (es) | Formulaciones farmacéuticas, procesos para la preparación y métodos de uso | |
JP2016513650A5 (fr) | ||
FR2952372B1 (fr) | Nouveaux derives de mannopyranoside ayant une activite anticancereuse | |
BRPI0506615A (pt) | composição de moléculas de estrutura lipofìlica, comprimido e utilização de uma composição | |
MA50458A (fr) | Formulations topiques destinées au traitement d'affections dermatologiques comprenant la calvitie hippocratique | |
MA53521A1 (fr) | Nouveaux composés inhibiteurs de la protéase mpro et de la réplication du sars-cov2, leurs formulations et applications | |
FR3058060B1 (fr) | Composition pharmaceutique comprenant le beta-elemene, le lupeol, le cinnamaldehyde et/ou le 2-hydroxycinnamaldehyde et/ou le 2'-benzoyloxycinnalmaldehyde et/ou le beta-sitosterol et/ou la curcumine. | |
MA38521A1 (fr) | Formulation d'acétate d'abiratérone utilisé dans le traitement du cancer de la prostate resistant a la castration | |
FR3104946B1 (fr) | Formulation d’un dendrimère anti-inflammatoire pour le traitement de psoriasis | |
FR3028762B1 (fr) | Derives hydroxybisphosphoniques hydrosolubles de la doxorubicine |